By otakuyassine3@gmail.com 
Charles Schwab Investment Management Inc. raised its stake in Phreesia, Inc. (NYSE:PHR – Free Report) by 10.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 493,448 shares of the company’s stock after acquiring an additional 46,209 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Phreesia were worth $12,415,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its position in shares of Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after buying an additional 905 shares during the last quarter. MetLife Investment Management LLC grew its stake in Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after acquiring an additional 1,120 shares during the period. R Squared Ltd acquired a new position in Phreesia in the 4th quarter valued at $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Phreesia by 9.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company’s stock worth $319,000 after purchasing an additional 1,258 shares during the period. Finally, BankPlus Trust Department acquired a new stake in shares of Phreesia during the fourth quarter worth $34,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.
Phreesia Trading Down 0.6 %
NYSE PHR opened at $27.45 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The firm’s fifty day simple moving average is $27.33 and its 200-day simple moving average is $24.07. The company has a market capitalization of $1.61 billion, a PE ratio of -18.68 and a beta of 1.03.
Insider Buying and Selling
In other news, SVP Amy Beth Vanduyn sold 1,311 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71. Following the transaction, the senior vice president now owns 115,633 shares in the company, valued at $3,076,994.13. This represents a 1.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Evan Roberts sold 3,519 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total transaction of $105,781.14. Following the transaction, the chief operating officer now directly owns 741,197 shares in the company, valued at $22,280,381.82. The trade was a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 162,442 shares of company stock worth $4,611,300. Insiders own 5.80% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on PHR shares. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Truist Financial lifted their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Finally, Citigroup lifted their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $31.33.
Check Out Our Latest Stock Analysis on PHR
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Recommended Stories
Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR – Free Report).
Receive News & Ratings for Phreesia Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Phreesia and related companies with MarketBeat.com’s FREE daily email newsletter.